SOPHiA GENETICS SA closed at $6.62 on Nov 5, down 5.02%, 25.8% below its 52-week closing high. Volume of 759.1K shares was 1.20× its 20-day average (close to normal).
Split-adjusted performance: -7.4% over one month, +22.6% over six months, +41.5% over one year.
Short interest was 1.0M shares at the Oct 15 settlement, down 10.8% from the prior report (2.0% of float, 1.4 days to cover).
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
What is SOPH's market cap?
$567.06M, based on the Nov 5 close of $6.62.
Does SOPHiA GENETICS SA pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SOPH is sold short?
1.0M shares, 2.0% of float, as of Oct 15, 2026.
About SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
